Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2019-11-14 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2019-11-14 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 14, 2019, announcing the financial results for the second quarter (Q2FY20) ended September 30, 2019. It contains detailed financial highlights including revenue, EBITDA, net profit, and EPS for Q2FY20 and H1FY20, along with business and operational highlights. The document also mentions an upcoming earnings call and provides dial-in details. The content is typical of an Earnings Release, which is an initial announcement of quarterly financial results with key highlights. The document length is 7859 characters, which is sufficient to include substantive financial data and analysis, not just a brief announcement or a link to a report. Therefore, this document should be classified as an Earnings Release (ER).
2019-11-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Neuland Laboratories Limited to stock exchanges regarding the outcome of a Board Meeting held on November 14, 2019. It specifically mentions the approval of unaudited financial results for the quarter and half-year ended September 30, 2019. The document includes the unaudited standalone financial results and a limited review report by the statutory auditors. The presence of detailed financial data for the quarter and half-year, along with auditor's review, indicates this is an Interim / Quarterly Report. The document is about unaudited quarterly and year-to-date financial results, which fits the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it merely an announcement or certification. The length and content confirm it is a substantive financial report for a period shorter than a full fiscal year.
2019-11-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement (2195 characters) about the upcoming earnings call for Neuland Laboratories Limited's Q2 FY 2019-20 results. It provides details about the date, time, dial-in numbers, and a brief company description. There are no actual financial results or detailed financial statements included. The document is clearly an invitation and information about the earnings call rather than the call transcript itself or the earnings release. According to the rules, such announcements about upcoming earnings calls are best classified as Regulatory Filings (RNS) since they do not contain the financial results or transcript but are regulatory announcements related to financial reporting events.
2019-11-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for November 14, 2019, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2019. It is a short announcement informing about the upcoming board meeting and the agenda, not the financial results report itself. The document length is only 2027 characters, which is quite short and consistent with a meeting notice rather than a full financial report. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain actual financial data or detailed report content.
2019-10-31 English
Board Meeting — Financial Results
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no textual content or substantive information. The true document length is only 220 characters, which is very short and contains no report or announcement details. There is no indication of any report, announcement, or filing type. Given the lack of content, this document cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without specific content.
2019-10-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.